Acerus Pharma

2486 Dunwin Drive
Mississauga
Ontario
L5L 1J9
Canada

Tel: 416-679-0771

Website: http://www.aceruspharma.com/

Show jobs for this employer

119 articles with Acerus Pharma

  • Acerus Pharmaceuticals Corporation announced that the Company has received a waiver letter from SWK Funding LLC related to the required Revenue Covenant for the third quarter of fiscal 2020 in its existing credit facility.

  • Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Kevin Hickey has joined the Company as Senior Vice President, US Commercial. Mr. Hickey will become a member of Acerus’ Senior Leadership Team. “I am very pleased to announce that Kevin is joining the Company in this important new role as we strengthen our comme

  • Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP; OTCQB:ASPCF) today reported its financial results for the three and six-month period ended June 30, 2020. Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Second Quarter Highlig

  • Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it will issue second quarter 2020 financial and operating results on Tuesday August 11, 2020 before the market opens. The Company will host an investor conference call that same day, August 11, at 10:00 a.m. Eastern Time, to discuss these results. To access the call live, please dial 416-406-0743 or 1-800-898-3989 and use

  • Acerus Announces Resumption of NATESTO ® Shipments Product En Route to United States and Taiwan TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a speciality pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced that production of new batches of NATESTO ® (testosterone nasal gel) is underway and shipments are already in transit to several key ma

  • Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPCF) today announced that Dr. Christopher Sorli, MD, PhD, FACE will join the Company as Chief Medical Officer, effective August 3, 2020, and will become a member of Acerus’ Senior Leadership Team. “I am very pleased to announce that Dr. Sorli is joining the Company in th

  • Acerus Announces Launch of NATESTO ® Specialty Sales Team in the United States Initially 22 in Size, Dedicated Staff to Target Urologists and Endocrinologists TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products for men’s health, today announced the launch of a dedicated sales team to promote the Company’s key product,

  • Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP, OTCQB: ASPF) today announced that it has commenced litigation against Recipharm Limited (“Recipharm”), a wholly-owned subsidiary of Recipharm AB (RECI-B.ST), in the Commercial Court of London. Acerus alleges that the suspension of Recipharm’s manufacturing lice

  • Acerus Announces Significant Improvement in NATESTO ® Insurance Coverage in the United States NATESTO ® now covered as a Preferred Brand by leading national pharmacy benefits manager TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a specialty pharmaceutical company focused on the commercialization of novel prescription products in Men’s Health, today announced that, as of July 1, 2020, Express Scripts, Inc., on

  • Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2020 (“Q1-2020). Unless otherwise noted, all amounts are in US dollars and are prepared in accordance with International Financial Reporting Standards (“IFRS”). Q1-2020 Highlights Refinancing transactions provide $18 million of new capital to suppor

  • Acerus Pharmaceuticals Corporation announced that Norma Beauchamp has resigned as a member of the Company's Board of Directors.

  • Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the appointment of Dr. Geoff Cotton, MB BS, MBA to its Board of Directors. Dr. Cotton is a healthcare executive, venture capital adviser, and angel investor with 20 years experience in the pharmaceutical industry. He spent over 17 years with Gilead Sciences Inc. in Medical Affairs and Commercial roles of increasing responsibility culminating in leadership of the Glo

  • Acerus Announces Publication of Results for NATESTO ® Spermatogenesis Study in Journal of Urology

  • Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it has received a Notice of Deficiency (“NOD”) for its avanafil New Drug Submission (NDS). Health Canada has requested the provision of additional quality information related to the avanafil drug substance in alignment with Intern

  • Acerus Pharmaceuticals Corporation issued an update on the Company’s activities in relation to the current worldwide COVID-19 pandemic.

  • Acerus Pharmaceuticals Corporation will announce financial results for the three and twelve month periods ending December 31, 2019 on Wednesday, March 4, 2020 before the market opens.

  • Feb. 21, 2020 14:55 UTC TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) is pleased to announce today’s closing of the refinancing transactions previously announced on February 12, 2020 (the “Refinancing Transactions”). Acerus received US$18,000,000 in gross proceeds from the private placement of 449,148,891 common shares of the Company (the “Common Shares”) to First Generation Capital Inc. (“First Generation”) and

  • Acerus Pharmaceuticals Corporation announced that it has entered into agreements with First Generation Capital, Inc. in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC in respect of an amendment to the Company’s existing credit facility with SWK.

  • Feb. 5, 2020 13:30 UTC Acerus Announces Acceptance of Two NATESTO ® Clinical Studies for Presentation at the American Urological Association Annual Scientific Program TORONTO--( BUSINESS WIRE )-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of two NATESTO ® clinical studies for presentation at the American Urological Association’s AUA2020 Scientific Program.

  • Acerus Pharmaceuticals Corporation announced the acceptance of a scientific abstract reporting the results of the NATESTO® Spermatogenesis Study by the Endocrine Society for presentation at their Annual Meeting.